magnesium aspartate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4517 18962-61-3

Description:

MoleculeDescription

Synonyms:

  • magnesium aspartate
  • Aspartic Acid, Magnesium (2:1) Salt
  • magnesium hydroaspartate
  • Molecular weight: 288.50
  • Formula: C8H12MgN2O8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Listless 94.01 29.45 22 3152 3227 90622046
Reduced facial expression 77.63 29.45 18 3156 2535 90622738
Apathy 67.37 29.45 22 3152 11018 90614255
Head discomfort 58.94 29.45 22 3152 16311 90608962
Vaginal flatulence 56.72 29.45 20 3154 12618 90612655
Reflexes abnormal 55.18 29.45 11 3163 758 90624515
Restlessness 54.24 29.45 26 3148 35694 90589579
Proctitis 53.04 29.45 20 3154 15239 90610034
Female genital tract fistula 49.98 29.45 20 3154 17848 90607425
Radiculopathy 49.30 29.45 20 3154 18485 90606788
Vaginal discharge 48.32 29.45 20 3154 19444 90605829
Colitis 47.73 29.45 30 3144 69912 90555361
Chronic sinusitis 47.66 29.45 21 3153 23781 90601492
Hypokalaemia 47.07 29.45 38 3136 131078 90494195
Urinary retention 46.98 29.45 24 3150 37720 90587553
Affect lability 42.95 29.45 18 3156 18045 90607228
Foreign body 42.30 29.45 11 3163 2483 90622790
Paraesthesia oral 39.02 29.45 20 3154 31639 90593634
Procedural pain 38.03 29.45 20 3154 33340 90591933
Oral candidiasis 36.88 29.45 20 3154 35435 90589838
Concomitant disease aggravated 36.09 29.45 14 3160 11504 90613769
Immobile 36.01 29.45 12 3162 6386 90618887
Vertigo 35.65 29.45 25 3149 69786 90555487
Pelvic fracture 35.63 29.45 15 3159 15204 90610069
Macular degeneration 35.60 29.45 20 3154 37950 90587323
Prescription drug used without a prescription 34.87 29.45 10 3164 3245 90622028
Encephalopathy 34.41 29.45 21 3153 46423 90578850
Atrial fibrillation 34.32 29.45 32 3142 133579 90491694
Periarticular disorder 34.22 29.45 5 3169 51 90625222
Cyclothymic disorder 33.29 29.45 6 3168 240 90625033
Cognitive disorder 31.19 29.45 23 3151 69384 90555889
Pericoronitis 29.98 29.45 5 3169 126 90625147

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fractional exhaled nitric oxide increased 118.19 31.03 25 2150 1584 42617576
Myoglobin blood increased 97.60 31.03 25 2150 3657 42615503
Plantar fasciitis 97.05 31.03 24 2151 3046 42616114
Sensation of foreign body 93.17 31.03 24 2151 3589 42615571
Brain natriuretic peptide increased 82.53 31.03 25 2150 6745 42612415
Infective exacerbation of chronic obstructive airways disease 80.18 31.03 19 2156 2014 42617146
Exostosis 69.51 31.03 21 2154 5610 42613550
Dysphonia 62.49 31.03 30 2145 28420 42590740
Pneumothorax 55.28 31.03 26 2149 23517 42595643
Obstructive airways disorder 54.04 31.03 26 2149 24733 42594427
Increased upper airway secretion 46.99 31.03 13 2162 2543 42616617
Nerve degeneration 45.14 31.03 8 2167 197 42618963
Eosinophilia 44.32 31.03 25 2150 32874 42586286
Dyspnoea exertional 44.12 31.03 29 2146 50119 42569041
Secretion discharge 43.89 31.03 16 2159 7619 42611541
Meningitis cryptococcal 43.78 31.03 13 2162 3270 42615890
Foreign body in throat 42.88 31.03 9 2166 547 42618613
Nasopharyngitis 38.83 31.03 33 2142 83963 42535197
Wheezing 37.16 31.03 27 2148 54754 42564406
Chest discomfort 35.72 31.03 28 2147 63588 42555572
Cardiac disorder 35.21 31.03 25 2150 48907 42570253
Hypomagnesaemia 33.97 31.03 20 2155 28468 42590692
Coronary artery disease 33.12 31.03 25 2150 53695 42565465
Bronchospasm 32.62 31.03 15 2160 12870 42606290

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fractional exhaled nitric oxide increased 81.76 26.29 16 5067 760 110583456
Listless 80.85 26.29 22 5061 4493 110579723
Infective exacerbation of chronic obstructive airways disease 73.60 26.29 19 5064 3171 110581045
Reduced facial expression 71.06 26.29 19 5064 3632 110580584
Myoglobin blood increased 54.78 26.29 16 5067 4216 110580000
Apathy 53.23 26.29 22 5061 16217 110567999
Meningitis cryptococcal 52.91 26.29 16 5067 4746 110579470
Vaginal flatulence 52.17 26.29 20 5063 12124 110572092
Plantar fasciitis 51.83 26.29 16 5067 5085 110579131
Head discomfort 49.90 26.29 22 5061 18978 110565238
Proctitis 49.03 26.29 21 5062 16906 110567310
Reflexes abnormal 48.81 26.29 11 5072 1036 110583180
Female genital tract fistula 46.22 26.29 20 5063 16499 110567717
Vaginal discharge 44.67 26.29 20 5063 17888 110566328
Nerve degeneration 43.31 26.29 8 5075 278 110583938
Atrial fibrillation 43.26 26.29 53 5030 229589 110354627
Radiculopathy 43.20 26.29 20 5063 19316 110564900
Chronic sinusitis 41.14 26.29 21 5062 25063 110559153
Sensation of foreign body 41.06 26.29 15 5068 7960 110576256
Macular degeneration 41.04 26.29 20 5063 21639 110562577
Pyrexia 40.55 26.29 111 4972 898154 109686062
Hypomagnesaemia 39.56 26.29 28 5055 60342 110523874
Brain natriuretic peptide increased 39.51 26.29 16 5067 11193 110573023
Increased upper airway secretion 39.13 26.29 13 5070 5219 110578997
Foreign body in throat 38.00 26.29 9 5074 1054 110583162
Affect lability 37.70 26.29 18 5065 18619 110565597
Foreign body 37.34 26.29 11 5072 2984 110581232
Restlessness 36.65 26.29 26 5057 56233 110527983
Colitis 36.08 26.29 33 5050 102290 110481926
Constipation 34.29 26.29 60 5023 357726 110226490
Febrile neutropenia 34.17 26.29 56 5027 316711 110267505
Paraesthesia oral 32.76 26.29 20 5063 33651 110550565
Pelvic fracture 32.74 26.29 15 5068 14139 110570077
Hypokalaemia 32.56 26.29 41 5042 182407 110401809
Procedural pain 31.75 26.29 20 5063 35545 110548671
Immobile 30.65 26.29 12 5071 7690 110576526
Vertigo 30.59 26.29 28 5055 86842 110497374
Cognitive disorder 30.41 26.29 28 5055 87483 110496733
Hyponatraemia 28.36 26.29 42 5041 217611 110366605
Concomitant disease aggravated 27.70 26.29 14 5069 16350 110567866
Urinary retention 27.58 26.29 24 5059 69659 110514557
Oral candidiasis 27.58 26.29 20 5063 44740 110539476
Pericoronitis 27.35 26.29 5 5078 164 110584052
Prescription drug used without a prescription 27.05 26.29 10 5073 5486 110578730
Renal neoplasm 26.37 26.29 8 5075 2398 110581818

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A12CC05 ALIMENTARY TRACT AND METABOLISM
MINERAL SUPPLEMENTS
OTHER MINERAL SUPPLEMENTS
Magnesium

Related Drugs by ATC class:

A12CC Magnesium 9 drugs
magnesium chloridemagnesium citratemagnesium gluconatemagnesium lactatemagnesium levulinatemagnesium orotatemagnesium oxidemagnesium pidolatemagnesium sulfate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Constipation indication 14760008 DOID:2089
Hypokalemia indication 43339004
Indigestion indication 162031009
Hypomagnesemia indication 190855004
Incomplete passage of stool indication 249515001
Hypokalemia Prevention indication
Hyperkalemia contraindication 14140009
Complete atrioventricular block contraindication 27885002
Gastrointestinal ulcer contraindication 40845000
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Diarrhea contraindication 62315008
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Gastroparesis contraindication 235675006
Chronic diarrhea contraindication 236071009
Hyporeninemic hypoaldosteronism contraindication 236464008
Familial hyperkalemic periodic paralysis contraindication 304737009 DOID:14451
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4030488 VUID
N0000182443 NUI
7018-07-7 SECONDARY_CAS_RN
4030488 VANDF
CHEBI:754115 CHEBI
CHEMBL2109228 ChEMBL_ID
DB13359 DRUGBANK_ID
R17X820ROL UNII
142131 RXNORM
d05397 MMSL
003851 NDDF
421128005 SNOMEDCT_US
421363009 SNOMEDCT_US
C0543448 UMLSCUI
D001224 MESH_DESCRIPTOR_UI
56841975 PUBCHEM_CID
R17X820ROL INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dermamed Nutrition for troubled skin HUMAN OTC DRUG LABEL 7 69711-687 CAPSULE, GELATIN COATED 50 mg ORAL OTC monograph not final 10 sections